NEW DELHI New Delhi: A Japanese study has revealed the important role of intestinal absorption of fat in the intestine in preventing diet-induced fatty liver disease. Accumulation of fat in the liver is induced by high-fat diet and obesity and is a rapidly is becoming a prevalent global health concern. Characterized by excessive fat accumulation in the liver, this condition poses significant risk for various metabolic disorders.
While the majority of existing research focuses on fat metabolism within the liver, emerging findings emphasize the important role of the intestine in this complex process. Researchers at Fujita Health University in Japan discovered in a study on rats that glucagon, GLP How key hormones such as proglucagon-derived peptides (PGDPs), including GLP-1 and GLP-2, influence fat absorption and hepatic fat formation. PGDPs are generally known as key hormones regulating lipid metabolism in the liver. .
The study, published in the journal Nutrients, examined the response of mice to a high-fat diet (HFD) for seven days to shed light on a potential new strategy for preventing fatty liver.
Yusuke Seno, associate professor at the university, said, “When we subjected GCGKO mice (lab-created mice in which one gene has been inactivated) and control mice to a HFD for a week, the hepatic free fatty acids in the GCGKO mice were significantly reduced. Significantly reduced increases in fatty acid (FFA) and triglyceride levels were observed, as well as reduced adipose tissue weight.”
These effects were attributed to decreased lipid absorption despite reduced fat-burning capacity in the liver. The findings showed that the absence of PGDP prevents diet-induced fatty liver by reducing intestinal fat absorption. Notable Importantly, the study also underlined the complex relationships between diet, hormonal responses, and intestinal microbiota.
Mice fed a high-fat diet showed remarkable changes in gut bacteria, including an increase in Parabacteroids and a decrease in Lactobacillus – both of which were associated with resistance to obesity. Cino said the study showed how “GLP-2 And oral dual antagonists of glucagon may emerge as potential treatments for obesity and fatty liver, especially given their role in insulin sensitivity and lipid metabolism”.
Comments are closed.